At the 67th American Society of Hematology (ASH) Annual Meeting, Gilead Sciences and its subsidiary Kite showcased a suite of new data underscoring major progress in cell therapy for blood cancers. As reported by Business Wire, with 21 abstracts and five oral presentations, the companies highlighted advances in CAR T-cell therapies that promise broader access, improved safety, and curative potential for patients with challenging hematologic malignancies.
Anito-cel: A New Hope for Multiple Myeloma
A central focus was updated results from the pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed/refractory multiple myeloma. This innovative BCMA-directed CAR T-cell therapy, developed in collaboration with Arcellx, was shown to have a favorable safety profile, with no delayed neurotoxicities such as Parkinsonism, cranial nerve palsies, or Guillain-Barré syndrome observed. These findings suggest anito-cel could offer an effective and safer treatment option for patients facing limited choices, with the potential for administration in community settings and reduced caregiver burden.
Next-Generation CAR T Therapies: Dual Targeting for B-Cell Malignancies
Kite also introduced data on next-generation bicistronic autologous CAR T-cell therapies, KITE-363 and KITE-753. These therapies are engineered to target two antigens (CD19 and CD20) commonly found on cancerous B-cells and incorporate two co-stimulatory domains to enhance immune response. This dual-targeting strategy is designed to minimize cancer relapse due to antigen loss and may improve safety, potentially allowing treatment outside the hospital and increased patient access.
Yescarta: Expanding Curative Potential in Large B-Cell Lymphoma
Yescarta® (axicabtagene ciloleucel), Kite’s flagship CD19-directed CAR T-cell therapy, continues to demonstrate its transformative role. A key presentation combined four-year follow-up data from the ZUMA-7 trial (in autologous stem-cell transplant-eligible patients) and two-year data from ALYCANTE (in transplant-ineligible patients) for relapsed/refractory large B-cell lymphoma (LBCL). The results showed consistent efficacy, safety, and quality of life improvements across both groups, reinforcing Yescarta’s value as a potentially curative, one-time therapy—regardless of stem cell transplant eligibility.
Pipeline and Real-World Insights
Beyond clinical trials, Gilead and Kite presented real-world evidence analyses on patient outcomes, healthcare resource utilization, and treatment equity. These studies support ongoing efforts to optimize patient access and inform best practices for CAR T-cell therapy deployment globally.
Looking Ahead
Gilead and Kite’s presentations at ASH 2025 demonstrate their commitment to transforming cancer care through innovative cell therapies. By advancing new CAR T-cell constructs like anito-cel, KITE-363, and KITE-753, and expanding indications for approved therapies like Yescarta, the companies are opening new frontiers for patients with relapsed or refractory blood cancers. The data signal a future where more patients can benefit from these potentially life-saving treatments, with improved safety, efficacy, and accessibility.
